Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2004 | 12-2003 | 09-2003 | 06-2003 | 03-2003 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,370 | -30,590 | -24,650 | -17,570 | -10,680 |
| Depreciation Amortization | 850 | 4,660 | 3,420 | 2,180 | 1,030 |
| Other Working Capital | -690 | -1,180 | -1,450 | -2,840 | -350 |
| Other Operating Activity | -1,160 | 1,640 | 2,510 | 2,740 | 3,040 |
| Operating Cash Flow | $-6,370 | $-25,470 | $-20,170 | $-15,490 | $-6,960 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -120 | -1,170 | -1,090 | -720 | -430 |
| Other Investing Activity | -11,230 | 16,610 | 17,400 | 12,590 | 9,880 |
| Investing Cash Flow | $-11,350 | $15,440 | $16,310 | $11,870 | $9,450 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 41,060 | 8,930 | 7,070 | -280 | -240 |
| Financing Cash Flow | $41,060 | $8,930 | $7,070 | $-280 | $-240 |
| Exchange Rate Effect | 140 | 290 | 190 | 190 | 80 |
| Beginning Cash Position | 8,550 | 9,350 | 9,350 | 9,350 | 9,350 |
| End Cash Position | 32,030 | 8,550 | 12,760 | 5,630 | 11,680 |
| Net Cash Flow | $23,480 | $-800 | $3,410 | $-3,710 | $2,330 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,370 | -25,470 | -20,170 | -15,490 | -6,960 |
| Free Cash Flow | -6,370 | -25,470 | -20,170 | -15,490 | -6,960 |